Is NewAmsterdam Pharma Company N.V. (NAMS) a Buy, Sell, or Hold?
NASDAQ : NAMS
NewAmsterdam Pharma Company N.V.
$27.98 USD
-$2.24 (-7.41%)
- Volume
- 890.46K
- Average Volume
- 1.31M
- Market Capitalization
- $3.27B
- P/E Ratio
- -15.46
- Dividend Yield
- 0.00%
- Price Target
- $48.00
- Year High
- $42.21
- Year Low
- $21.14
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.76
Company Overview
NASDAQ
Michael Davidson
Biotechnology
Healthcare
NAMS
100
NL
USD
Liquidity Metrics
0.00
9.76
9.76
6.79
0.00
Sales & Valuation
$22.5M
144.96
5.09
-23.00
-1.17
Profitability
-$1.75
-$203.82M
-942.76%
-942.76%
-29.80%
-29.04%
P/E Metrics
-15.46
2.57
2.57
Analyst Price Target & Rating
$48.00
$58.00
$45.00
2/5
10 Analysts
-41.71%
Financial Health Scores
29.33
1/9
$590.62M
$732.64M
$67.42M
-$212.73M
Key Metrics (TTM)
$3.08B
136.28
-14.47
9.76
-29.80%
-32.35%
-5.81%
-4.02%
-5149 days
Company Executives
| Name | Title |
|---|---|
| Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director |
| Juliette Audet | Chief Strategy & Business Officer |
| Chris Deluzio | Executive Vice President of Sales Enterprise Operations |
| Louise Kooij | Chief Accounting Officer |
| Douglas F. Kling | Chief Operating Officer |
| Michael Harvey Davidson FACC Facp. | CEO, President & Executive Director |
| Michael F. Marino | Chief Legal Officer & Corporate Secretary |
| Maryellen McQuade | Chief People Officer |
| Mayur Amrat Somaiya | Chief Financial Officer |
| Matthew Philippe | Executive VP & Head of Investor Relations |
Poll Results
No votes yet today — be the first to share your view!
About NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. ...
2026-07-26 13:59:00
/PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS oder „NewAmsterdam" oder das „Unternehmen"), ein biopharmazeutisches Unternehmen in der späten
NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill
2026-07-25 23:58:33
NewAmsterdam Pharma offers differentiated potential with obicetrapib, targeting comprehensive cardiovascular risk reduction beyond LDL-C lowering. NAMS's valuation is elevated, reflecting pipeline potential rather than current revenues; clinical and regulatory execution, especially PREVAIL, are critical to justify this premium. Upcoming catalysts include European regulatory decisions (H2 2026), PREVAIL interim analysis (Q4 2026/Q1 2027), and RUBENS topline data (year-end 2026).
2026-07-25 13:39:00
/PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS (ou « NewAmsterdam » ou la « Société »), une société biopharmaceutique spécialisée dans les
2026-07-24 10:13:00
/PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing
2026-07-24 08:00:00
- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe - - Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, and TANDEM data - - European Commission decision expected in 2H26 - NAARDEN, The Netherlands and MIAMI and FLORENCE, Italy, July 24, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, along with partner Menarini Group (“Menarini”), today announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has adopted a positive opinion recommending marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination (“FDC”)) for patients with primary hypercholesterolemia, both heterozygous familial (“HeFH”) and non-familial or mixed dyslipidemia.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 16:01:00
NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 28,700 of NewAmsterdam's ordinary shares to four non-executive new hires.
2026-07-01 08:00:00
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for the prevention of early Alzheimer's disease, at the Alzheimer's Association International Conference (AAIC) 2026, taking place on July 12 – 15, 2026 in London, United Kingdom.
2026-06-10 00:52:09
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Frequently Asked Questions
-
What is the current NewAmsterdam Pharma Company N.V. (NAMS) stock price?
-
NewAmsterdam Pharma Company N.V.(NASDAQ:NAMS) stock price is $27.98 in the last trading session. During the trading session, NAMS stock reached the peak price of $42.205 while $21.135 was the lowest point it dropped to. The percentage change in NAMS stock occurred in the recent session was --7.41% while the dollar amount for the price change in NAMS stock was -$2.24.
-
NAMS's industry and sector of operation?
-
The NASDAQ listed NAMS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NAMS?
-
Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director
Juliette Audet | Chief Strategy & Business Officer
Chris Deluzio | Executive Vice President of Sales Enterprise Operations
Louise Kooij | Chief Accounting Officer
Douglas F. Kling | Chief Operating Officer -
How many employees does NAMS have?
-
Number of NAMS employees currently stands at 100. NAMS operates from Gooimeer 2-35, Naarden, NH 1411 DC, NL.
-
Link for NAMS official website?
-
Official Website of NAMS is: https://www.newamsterdampharma.com
-
How do I contact NAMS?
-
NAMS could be contacted at phone #31 35 206 2971 and can also be accessed through its website. NAMS operates from Gooimeer 2-35, Naarden, NH 1411 DC, NL.
-
How many shares of NAMS are traded daily?
-
The average number of NAMS shares traded daily for last 3 months was 1.31M.
-
What is the market cap of NAMS currently?
-
The market value of NAMS currently stands at $3.27B with its latest stock price at $27.98